CWA
REGN icon

Carolina Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Carolina Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$3.15K – 284
2025
Q2 		$3.15K Hold
6
– – ﹤0.01% 208
2025
Q1 		$3.81K Hold
6
– – ﹤0.01% 203
2024
Q4 		$4.27K Hold
6
– – ﹤0.01% 208
2024
Q3 		$6.31K Buy
+6
New +$6.68K ﹤0.01% 206

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carolina Wealth Advisors's REGN Position: Q3 2025 in Review

Carolina Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 6 shares — an estimated $3.15K sold.

Carolina Wealth Advisors first reported a position in REGN in Q3 2024 and held it in 4 quarters. The position peaked at $6.31K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Carolina Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Carolina Wealth Advisors sold 6 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $3.15K.
  • Carolina Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Carolina Wealth Advisors's Regeneron Pharmaceuticals position peaked at $6.31K in Q3 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Carolina Wealth Advisors's 13F filing for Q3 2025, filed 7 Oct 2025.